Triptorelin Embonate
Recommended · restricted OncologyAuthority RequiredFirst-line line
Locally advanced or metastatic carcinoma of the prostate.
1
Submissions
2006–06
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Nov 2006Recommended · restricted
vs goserelin acetate
- PBS listing · Authority Required
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated
The PBAC recommended listing on a cost minimisation basis with goserelin acetate with the equi-effective doses being triptorelin embonate (Diphereline®) 3.75mg once monthly, for duration as necessary, and goserelin acetate (Zoladex®) 3.6mg once monthly for duration as necessary; and triptorelin embonate (Diphereline®), 11.25mg once every three months, for duration as necessary, and goserelin acetate (Zoladex®), 10.8mg once every three months for duration as necessary. PBAC · 2006
Decision context
PopulationMen with locally advanced (Stage C) or metastatic (Stage D) carcinoma of the prostate.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2006 | Recommended · restricted | goserelin acetate | — | RCT · OS |